Insmed Incorporated
INSM
Rank in Stocks
#1108
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Share Price
$95.65
Last synced: 2026-10-19
Market Cap
$20.89B
Change (1 day)
-0.65%
Change (1 year)
-43.04%
Country
US
Trade Insmed Incorporated (INSM)
Category
Healthcare
Stock split history for Insmed Incorporated (INSM)
Insmed Incorporated stock (symbol: INSM) underwent a total of 2 stock splits.
The most recent stock split occurred on Mar 03, 2011.
One INSM share bought prior to Jul 31, 2000 would equal to 0.025 INSM shares today.
The most recent stock split occurred on Mar 03, 2011.
One INSM share bought prior to Jul 31, 2000 would equal to 0.025 INSM shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| 2011-03-03 | 1:10 | x0.1 | x0.025 |
| 2000-07-31 | 1:4 | x0.25 | x0.25 |
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
